| __timestamp | BioMarin Pharmaceutical Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 2983000000 |
| Thursday, January 1, 2015 | 402271000 | 3426000000 |
| Friday, January 1, 2016 | 476593000 | 3398000000 |
| Sunday, January 1, 2017 | 554336000 | 3878000000 |
| Monday, January 1, 2018 | 604353000 | 4056000000 |
| Tuesday, January 1, 2019 | 680924000 | 4381000000 |
| Wednesday, January 1, 2020 | 737669000 | 5151000000 |
| Friday, January 1, 2021 | 759375000 | 5246000000 |
| Saturday, January 1, 2022 | 854009000 | 5673000000 |
| Sunday, January 1, 2023 | 937300000 | 6090000000 |
| Monday, January 1, 2024 | 1009025000 | 6091000000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and BioMarin Pharmaceutical Inc. have shown distinct approaches to handling these costs. From 2014 to 2023, Gilead Sciences consistently reported higher SG&A expenses, peaking at approximately $6.09 billion in 2023, a 104% increase from 2014. In contrast, BioMarin's SG&A expenses grew by 210% over the same period, reaching around $937 million in 2023. This disparity highlights Gilead's larger scale of operations, while BioMarin's rapid growth in expenses suggests aggressive expansion strategies. Understanding these trends provides valuable insights into each company's operational efficiency and strategic priorities. As investors and industry analysts evaluate these giants, the ability to manage SG&A costs effectively remains a key indicator of financial health and competitive advantage.
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
AbbVie Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated